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Background: Hospitals are under increasing pressure to realise cost savings and improve quality of 
services. However, the relationship between hospital costs and quality is largely unexplored in 
publicly funded health systems, such as the English NHS. 
Objective: To determine the association between hospital costs and process quality of care and 
hospital costs and health outcomes in England.  
 
Design: Observational study. Cost-process quality association is examined calculating pairwise 
correlations between hospital cost indicators and process quality indicators at the hospital level. 
Cost-health outcomes association is examined using a logistic regression and instrumental variable 
approach at the patient level.  
 
Setting: NHS hospital trusts in England with at least 100 annual admissions of patients with a 
fractured neck of femur, acute myocardial infarction (AMI) or stroke. In the cost-process quality 
analysis, hospitals are examined in 2010. In the cost-health outcomes analysis, hospitals are followed 
from 2006 to 2010. 
 
Patients:  217,810 hip fracture (age ≥ 65), 219,405 AMI and 250,796 stroke (age ≥ 55) emergency 
admissions. Only patients who experienced no emergency admissions in the previous year are 
included. 
 
Main outcome measures: Hospital average costs for selected cohort of patients are obtained by 
matching data from the National Schedules of Reference Costs to patient discharge information in 
the Hospital Episode Statistics. Quality of care is measured using a number of process quality 
indicators produced by the National Audit of Falls and Bone Health in Older People, the Myocardial 
Ischemia National Audit Project (MINAP) and the National Sentinel Stroke Clinical Audit. Main 
patient health outcomes examined are 30 days in-hospital mortality and 28 days emergency 
readmissions. 
 
Results: Results from the empirical analyses are specific to the cohort of patients considered. In the 
stroke cohort, we find evidence of a positive and significant correlation between costs and a number 
of indicators of evidence based best practice in the care provided. Also, we find a negative 
association between costs and 30-days mortality (0.862 odds; 0.829-0.966, 95% confidence interval) 
and no association with 28-days readmissions (1.040 odds; 0.959-1.129, 95% CI). In the AMI cohort, 
we find some evidence of a positive and significant correlation between costs and some indicators of 
treatment intensity and hospital access to technology. Also, we find a negative correlation between 
costs and indicators of prompt intervention. No association is found between costs and 30-days 
mortality (1.005 odds; 0.887-1.138, 95% CI) and 28-days readmissions (1.040 odds ratio; 0.956-
1.132, 95% CI). In hip fracture cohort, we find little evidence of a positive association between 
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hospital average costs and process quality indicators and no association between hospital average 
costs and 30-days mortality (0.997 odds ratio; 0.930-1.068 95% CI). 
 
Conclusion: The relationship between hospital costs and quality is heterogeneous across different 
patient cohorts. Using micro-level measures of costs and quality allows for the identification of 
hospital services with larger potential for cost savings and quality improvements. In contrast, 








In many developed health systems, hospitals are coming under increased pressure to reduce the 
costs of their services and at the same time improve the quality of care.  The call for cost 
containment has been placed at the centre of the political agenda in European countries with 
universal access to care funded by the taxpayer.  In England, the Department of Health is 
implementing an ambitious programme of cost savings aimed at securing a £20bn spending 
reduction by 2015 without compromising frontline services or the quality of care. In particular, the 
National Health Service (NHS) providers are required to secure 4 per cent efficiency savings per year, 
and the average price for prospectively reimbursed services fell by 1.5 per cent in 20111.  
 
In this context, understanding the relationship between hospital cost and quality of care is essential 
in order to identify services with the greatest potential for improvements and to avoid unwanted 
consequences on the quality of care and patient health.  However, examining the relationship 
between costs and quality is intrinsically challenging. Patients at higher risk of a negative health 
outcome might need more resources, resulting in both higher hospital costs and worse health 
outcomes. Alternatively, the opposite might sometimes be true: patients at higher risk of a negative 
health outcome might not be fit for intensive surgical treatments, or die at an early stage of 
treatment, reducing the cost of their care. This can result in lower hospital costs and worse health 
outcomes being observed. In the absence of complete data on patient characteristics and health 
risks, it is therefore difficult to assess accurately the net effect on the relationship between patient 
health outcomes and hospital costs without recourse to advanced analytic methods. 
 
Most of the empirical studies so far are based on the US population and health system2-12 and 
provide contrasting evidence12. A number of studies focusing on short and long term mortality 
within a single state find that higher spending is associated with better health outcomes2 8 10.  A 
common feature of such studies is that they use hospital spending at the end of a patient’s life to 
classify hospitals into groups with different propensities for spending and then examining the 
association between spending group and risk adjusted mortality rates from particular conditions. 
The rationale for such an approach is that end-of-life hospital spending is likely to be correlated with 
spending for other admissions, but it should not be contaminated by unmeasured health risks 
amongst the general patient population that cannot be controlled for in the statistical analysis. This 
approach assumes that hospitals spending more at the end of a patient’s life also spend more for 
other admissions without necessarily attracting patients at higher risk of negative health outcomes 
than other hospitals.  
 
A similar positive association between spending and outcomes is found in a study examining patient 
mortality and hospital readmissions after one year from index hospitalisation in the population of US 
veterans and examining mortality after one year of hospital discharge for AMI admissions9. The 
effect of patient level costs on health outcomes is measured using an instrumental variable (IV) 
approach that allows for unmeasured patient health risks in a similar fashion to the end-of-life 
spending approach. The authors use geographical differences in the Medicare Wage Index and 
general overhead costs across hospitals as instruments to randomise patients with different costs 
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and identify the effect of costs on health outcomes. Their assumption is that these instruments are 
correlated with patient costs, but uncorrelated with unmeasured health risks. 
  
In contrast a number of studies examining the whole US population find no or negative association 
between hospital spending and hospital process quality of care and patient health outcomes5-7 11. 
These studies use various methods and units of analysis including regions, hospital admissions and 
end-of-life spending approach. Their evidence suggests that equal health outcomes are achieved by 
institutions providing lower intensity of care or the same level of care at lower costs.  
 
In England, the association between hospital costs and quality of care is largely unexplored. Quality 
improvements in medical practice might be expensive, but can also save money by reducing the risk 
of adverse events and in-hospital length of stay. Moreover, improving complex process and 
organisations of services might generate even greater cost savings. However, there is no evidence as 
to whether such changes reduce or increase eventual costs in real settings. The existing evidence is 
limited to studies of simple clinical level changes that are effective in reducing adverse events, such 
as better antibiotic or antithrombolytic prophylaxis before surgery13.  However, in such studies it is 
difficult to include in the analysis all the direct and indirect costs associated with the implementation 
of the intervention. In real settings these elements are often likely to make the difference between a 
cost saving and a cost increasing intervention13 14.  
 
The absence of evidence from England can be explained by the lack until recent years of reliable and 
detailed data on hospital costs. From 2003 to 2008, there has been a progressive transformation of 
the hospital payment system from retrospective to prospective reimbursement based on an English 
system of diagnosis-related groups known as Healthcare Resource Groups (HRGs). This change has 
been accompanied by the parallel introduction of a uniform costing system for hospital activity that 
apportions hospital variable costs and overheads to the service units using a top down allocation 
procedure15.  As part of this transformation, English hospitals have to report detailed data on their 
service costs centrally. These returns are then used as a basis for calculating the fixed HRG tariff for 
prospective reimbursement of hospital services16. Following the change in the payment system, 
reasonably reliable data on the cost of hospital services are now available in England and a number 
of empirical applications have made extensive use of such data in the analysis of hospital efficiency 
and performance17 18. One study18 examines the variation in hospital costs associated with patient 
reported outcome measures (PROMS). The authors examine a basket of elective procedures, i.e. hip 
and knee replacement, varicose vein surgery and groin hernia repair, and assess patient level costs 
against hospital level average health gains as measured by the EuroQoL-5D and EQ-VAS. They use a 
cross-section of 2009 hospital administrative data and cost returns and find a negative but not 
statistically significant association between costs and hospital average health gains.   
 
Evidence on the relationship between hospital costs and quality nevertheless remains limited.   
There are two aims of the present study. The first is to investigate whether hospitals reporting 
higher costs provide better process quality of care as measured by indicators of treatment intensity, 
access to technology, provision of prompt intervention and adherence to medical guidelines on best 
practice. The second is to investigate whether hospitals reporting higher costs produce better 
patient health outcomes as measured by 30 days and all in-hospital mortality and 28 and 365 days 
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emergency readmissions. We examine three separate cohorts of patients: stroke, acute myocardial 





Study Design Overview 
 
Our empirical investigation consists of two separate analyses:  
 
1. A cost-process analysis 
2. A cost-outcome analysis 
 
Higher costs might be associated with better process quality of care but might not be associated 
with better health outcomes, since a large number of processes of care can improve several aspect 
of patients’ health without affecting their mortality risk. Hence, we examine both processes of care 
and health outcomes in our study. 
 
In the cost-process analysis, the relationship between costs and process quality is investigated by 
calculating pairwise correlation coefficients between hospital costs and hospital process quality 
indicators. In this analysis, we are constrained by the data on process quality that are available for 
2010 only and at the level of hospital (e.g. proportion of compliance over total eligible cases) rather 
than at the level of patient within hospital. Therefore, we construct indicators of costs at the level of 
hospital and correlate these with hospital level indicators of process quality in 2010 only as 
described in the statistical analysis section. 
 
In the cost-outcome analysis, the relationship between costs and health outcomes is investigated at 
the level of patient using longitudinal cohorts with selected acute conditions admitted to NHS 
hospital trusts from 2006 to 2010. We employ a number of methods to remove potential 
confounding effects generated by unmeasured patient health risks. First, we examine emergency 
admissions of patients with similar primary diagnosis over a long time span (5 years).  Also, only 
patients experiencing no emergency admissions up to one year before the index hospitalisation are 
included.  This should reduce distortions caused by sicker patients choosing higher quality hospitals 
and random variations in hospital case-mix over time.  Second, for each diagnosis we use hospital 
average costs as opposed to patient level costs to avoid confounding effects from within hospital 
differences in patient health risks and survival bias. Third, we use an instrumental variable approach 
to control for potential residual correlation between hospital average costs and unmeasured health 





In the cost-process analysis, we use hospital level indicators of process quality provided by three 
national clinical audits on stroke, AMI and hip fracture. The samples of patients selected in the audit 




In the cost-outcome analysis, we examine separately three cohorts of patients admitted for acute 
conditions with high mortality rates and extensively studied in the literature of hospital costs and 
health outcomes. We include emergency admissions of patients with a primary diagnosis of stroke 
ICD-10 codes I60-I64 (n= 250,796), AMI ICD-10 codes I21-I22 (n= 219,405), hip fracture ICD-10 codes 
S72.0-S72.2 (n= 217,810) to NHS hospital trusts (i.e. acute public hospitals) from the financial year 
2006 to 2010.  
To reduce variation in the health risk of the studied population, we include only patients aged 55 
and over for stroke and AMI admissions and age 65 and over for hip fracture admissions.  Also, we 
exclude patients experiencing any sort of emergency admission one year before the index 
admission.  
 
We create an index spell of care following patients from first admission to final discharge across 
different specialists and hospital transfers. The patient cohorts are identified by using the diagnosis 
reported as reason for admitting the patient (primary diagnosis) in the index admission.  
 
To increase stability in the empirical analysis, we include only hospitals having at least 100 
admissions per year for the cohort of patients under scrutiny. This results in the exclusion of 4 
hospitals for stroke, 7 hospitals for AMI and 4 hospitals for the hip fracture cohort. The final sample 
of hospitals included in the analysis consists of 151 hospitals for stroke, 149 for AMI and 149 for hip 
fracture cohort. 
 
Finally, we exclude cost outliers by dropping patients below the 0.5 percentile and above the 99.5 
percentile of the cost distribution for each cohort. The exclusion of cost outliers prevents the 
analysis from being driven by extremely low cost or expensive patients, for whom there is a high 
likelihood of data errors. Similar exclusion thresholds are adopted by the Department of Health to 





Hospital average costs specific to each of the examined cohorts are used as the exposure variable. 
These are obtained by matching hospital cost returns to patient discharge records and then 
calculating averages of the costs of all HRG service units provided to patients within cohorts and 
hospitals. 
 
In England, hospitals cost their activity at the end of the financial year and service costs are 
calculated retrospectively following a top-down allocation procedure with total costs decomposed at 
the level of HRG service units within hospital speciality and type of admission (e.g. elective, non 
elective, day case, and non elective short stay). In the period covered by our analysis, the HRG4 
grouping system classifies hospital activity according to 1,400 different HRG service units. Hospitals 
allocate total costs to HRG service units following the principle of full absorption costing of the 
service provided, so that each reported HRG unit cost will include the direct, indirect and overhead 
costs associated with providing that treatment or care15.  Detailed costing rules and software to 
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generate final estimates are homogeneous across all hospitals and centrally regulated by the 
Department of Health.  Every year, all NHS hospitals are mandated to submit their HRG cost returns 
to the Department of Health, which in turn uses this information to calculate a national 
reimbursement tariff for each of the HRG service units, usually as an average of all hospital HRG cost 
returns16.   
 
An increasing number of hospitals are implementing a Patient Level Information and Costing System 
(PLICS) in order to improve the quality of their costs returns. Such systems are based on a bottom-up 
allocation procedure, with hospitals collecting cost information at the level of patient and then 
aggregating these data to calculate their HRG costs. PLICS were first implemented in 2009 following 
the recommendations of the NHS economic regulator (Monitor) and the Department of Health. In 
sensitivity analysis, we repeat our study in a subsample of 53 NHS hospitals using PLICS for their cost 
returns. 
  
We matched HRG service unit costs within hospital speciality and type of admission as reported in 
the hospital cost returns to their equivalent combination of services reported in the patient 
discharge records. Cost variation at the level of patient is generated by different care pathways and 
combination of HRG services provided to patients from admission to final discharge.  
 
Finally, hospital average costs are expressed at 2010 average prices in order to remove confounding 




Indicators of quality of care 
 
We examine a number of process quality and patient health outcome indicators. Process quality 
indicators are defined as share of compliance with best practice guidelines amongst eligible patients 
and are provided by a series of National Clinical Audits19-21 described in the data section. All process 
quality indicators are examined at the hospital level and refer to 2010 only (unless specified 
otherwise), since we have access to the indicators only reported in this aggregate format and for 
that year. In contrast, health outcomes are examined at the patient level from 2006 to 2010 for all 
cohorts and include 30 days and all in-hospital mortality and 28 days and 365 days emergency 
readmissions.  
 
In the stroke cohort, the following process quality indicators are examined:  
1. Spending at least 90% of stay on a stroke unit  
2. Screening for swallowing disorders within 24hrs after admission  
3. Brain scan within 24hours of stroke  
4. Aspirin or clopidogrel by 48 hours after stroke  
5. Physiotherapy assessment within 72hrs of admission  
6. Assessment by Occupational Therapist within 4 working days of admission 
7. Weighed at least once during admission  
8. Mood assessed by discharge 
9. Rehabilitation goals agreed by multi-disciplinary team by discharge 
10. Swallow assessment within 72hours  
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11. Initially admitted to a stroke unit  
12. Rehabilitation goals agreed by the multi-disciplinary team within 5 days of admission 
13. Diagnosis discussed with patient  
14. Admitted to stroke unit within 4 hours  
15. Initially admitted to a general assessment unit  
 
We also examine composite indicators:  
16. Receiving all key 12 indicators in 2010 (i.e. patients receiving all indicators 1-13 excl. 9)  
17. Receiving all key 9 indicators in 2010 (i.e. patients receiving all indicators 1-9) 
18. Receiving all key 9 indicators in 2008 (i.e. patients receiving all indicators 1-9 in 2008)  
 
In the AMI cohort, the following process quality indicators are examined:  
1. Hospital providing primary angioplasty 
2. Primary angioplasty within 90 mins of arrival at interventional centre 
3. Primary angioplasy within 150 mins of calling for help  
4. Primary angioplasy 150m of calling w direct adm to intervent centre 
5. Patients with direct admission to Interventional Centre  
6. Non ST elevation myocardial infarction (nSTEMI) patients admitted to cardiac unit or 
ward  
7. nSTEMI patients seen by a cardiologist or member of team  
8. nSTEMI patients referred for or having coronary angiography  
 
And secondary prevention medications: 
9. Aspirin 
10. Beta blocker 
11. Statins 
12. ACE inhibitor 
13. Clopidogrel/Thienopyridine inhibitor 
 
Finally, in the hip fracture cohort the following process-quality indicators are examined: 
1. Adequate analgesia within 60 min of admission 
2. Assessment of cognitive function within 72h of surgery 
3. Attempt to mobilise the patient within 24h of surgery 
4. Documented lying and standing blood pressure readings 
5. Patient attending exercise programme within 12w of fall 
6. Home hazard assessment of the patient’s own environment 
7. Anti-resorptive therapy for osteoporosis 
8. Written falls prevention info given to the patient or carer 






Patient records are obtained from the Hospital Episode Statistics (HES) dataset, which collects 
information on discharge cards of all NHS patients admitted in hospitals in England. The dataset 
contains detailed information on patient characteristics and care provided including: socio-
demographic characteristics, primary and up to 19 secondary diagnoses (ICD-10 codes), main 
operation and up to 23 secondary operations (OPCS-4 code), type of admission and discharge, 
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hospital transfers, specialists in charge of the patient care and the specialty where care is provided. 
We linked patient episodes of care hospital spells including hospital transfers (i.e. continuous 
inpatient spells) using anonymised identifiers and an algorithm used in previous studies22. Our 
analysis is based on admissions occurring from 2006 to 2010 of patients in selected cohorts. 
However, we also use patient admissions in 2005 and 2011 in order to exclude patients having an 
emergency admission up to one year before the index hospitalisation and to calculate mortality and 
readmissions occurring after the end of 2010.  
 
Hospital costs are obtained from organisation level data of the National Schedules of Reference 
Costs. The data include the average costs of all hospital services disaggregated at the level of HRG 
service unit within hospital, speciality and type of admission (elective, day case, emergency, short 
stay emergency). We collected data on hospital costs from 2006 to 2010 and match these with the 
patient records reported in the HES dataset. 
 
Hospital level process quality indicators are obtained from three National Clinical Audits conducted 
in 2010. Specifically, the National Sentinel Clinical Stroke Audit 201019 provided the process quality 
indicators for the stroke cohort. The audit sample consists of consecutive cases with a primary 
diagnosis of stroke (ICD-10 codes: I61, I63 and I64) admitted to hospitals between 1st April and 30th 
June 2010. Only hospitals directly admitting stroke patients were eligible to participate in the audit.  
Also, hospitals must have at least 20 cases in the 3 months period to be eligible. Data on 11,353 
cases were received from 158 hospital representing 100% of eligible trusts. 
 
The process quality indicators for the AMI cohort are obtained from the Myocardial Ischaemia 
National Audit Project20 (MINAP). Participating hospitals are requested to submit data on all patients 
admitted with a suspected AMI - 79,863 cases with a final diagnosis of myocardial infarction were 
reported for England and Wales in 201020. Hospital quality indicators are produced for hospitals 
reporting a minimum of 20 positive cases only. We find 138/140 hospitals included in our study 
meeting this requirement for at least one quality indicator.  
 
Process quality indicators for the hip fracture cohort are obtained from the report of the national 
audit of falls and bone health in older people 201021. For the clinical audit, all hospitals were asked 
to collect information on a minimum of 20 consecutive cases aged 65 and over admitted in 
emergency departments for a fractured hip following a fall during the period 1 April until 31 July 
2010. Unfortunately, the number of hospital trusts reporting a minimum of 20 eligible cases is 
variable across examined indicators and ranges from 16 to 102 hospital trusts out of 143 hospitals 
included in our study. Quality indicators based on less than 20 eligible cases are excluded from the 
analysis.  
 
Geographical variations in median and mean salary from 2006 to 2010 are obtained from the Annual 
Survey of Hours and Earnings. We use Travel to Work Areas (TTWA) calculated by the Office for 
National Statistics as the starting point of analysis. A Travel to Work Area is a collection of wards for 
which of the resident economically active population, at least 75% actually work in the area, and 
also, that of everyone working in the area, at least 75% actually live in the area23. There are 243 
TTWAs within the United Kingdom in 2007. We attributed TTWA level median and mean salary to 
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hospitals catchments areas (i.e. 20km fix radius from hospital postcode) using the Geoconvert 





The cost-process quality association is examined by calculating pairwise correlation coefficients at 
the hospital level. We examine three indicators of hospital costs:  
 
 Unadjusted cost indicator 
 Case-mix adjusted cost indicator 
 Case-mix adjusted in the subsample of hospitals using PLICS 
 
Unadjusted cost indicators are obtained by dividing hospital average costs by the Market Force 
Factor (MFF) payment index calculated by the Department of Health. Hospital average costs are 
calculated following the procedure described in the “Hospital Costs” section.  The MFF index adjusts 
hospital reimbursement payments for differences in unavoidable costs across hospitals, such us 
geographical differences in the cost of labour and capital24. The index ranges from 1.00 to 1.32 
meaning that hospitals at the top end of the range (in central London) receive 32% higher payments 
for each HRG service provided than those at the low end.  
 
Case-mix adjusted cost indicators allow for the differences in hospital average costs that are due to 
differences in their patient case-mix.  They are calculated as follows: first, patient level costs are 
regressed against patient characteristics (listed at the end of this section) and hospital fixed effects 
using linear regression. Second, using the estimated model, predicted patient level costs are 
calculated as a function of patient level characteristics setting the hospital fixed effects equal to 
zero.  Finally, the case-mix adjusted indicator is calculated as the ratio of the hospital unadjusted 
cost indicator to patient level predicted costs averaged within the hospital. The case-mix adjusted 
indicator equals 1 when unadjusted and case-mix expected hospital average costs are equal and is 
larger (smaller) than 1 when unadjusted hospital average costs are larger (smaller) than case-mix 
expected costs. The inclusion of hospital fixed effects in the model ensures that expected costs are 
based only on observed patient characteristics. It prevents hospital characteristics that might be 
correlated with the hospital case-mix from being washed out of the case-mix adjustment. For 
instance, hospitals with access to better technologies, such as primary angioplasty or brain scan, 
might attract higher proportions of sicker patients. If the characteristics of these patients were 
entered in the model but the hospital fixed effects were omitted, then the pure influence of patient 
complexity on average costs may be overstated. A discussion of methods to address this problem 
can be found elsewhere25. 
 
Case-mix adjusted indicators are commonly used in the literature, but sometime criticised as they 
may lead to bias if hospitals systematically differ in reporting case-mix or service costs’ 
information26. For sensitivity analysis, we recalculate the case-mix adjusted cost indicator in a 
subsample of hospitals that use PLICS to make their cost returns. The PLICS is a more accurate 




The cost-health outcomes association is investigated using logistic regression and instrumental 
variables. We estimate separate models of health outcomes for each cohort using patients as the 
unit of analysis and hospital average costs as the exposure. Hospital average costs mitigate potential 
endogeneity and censoring issues that would arise if individual level costs were to be used, while 
patient level observations allow us to control for individual risk and to make inference at the 
individual level. 
 
A potential endogenity problem nevertheless still arises if patients can select (or are selected into) 
hospitals with different levels of quality according to their health risk. For instance, hospitals with 
access to higher technology, such as primary angioplasty or brain scan, might attract higher 
proportions of patients with more severe AMI or Strokes. This might have the effect of raising the 
costs and worsening the health outcomes for such hospitals, and lead to estimation bias, if patient 
health risks are not fully controlled for in the analysis. Typically, randomised control trials avoid this 
problem by randomly allocating patients across hospitals with different average costs, but such a 
study design is unfeasible in our study. Instead, our method of analysis uses an instrumental variable 
that will act as a randomising device to rebalance the allocation of patients across hospitals. The 
instrument must hold the following characteristics: it must explain the variation in hospital costs but 
must not be correlated with unmeasured determinants of patient health outcomes. We find such 
characteristics in the area differences in mean and median salary, as used in a previous study9. 
Higher labour costs are likely to result in higher hospital average costs and also to influence 
management strategies for resource allocation and organisation of services. However, patient risk of 
negative health outcomes should not be correlated with area differences in salary after controlling 
for patient and hospital characteristics described below. 
 
We use a two-stage residual inclusion (2SRI) model described elsewhere27 and already used in 
healthcare9. In the first stage we regress hospital average costs against patient characteristics (as 
listed below) and the instrumental variables using a Generalised Linear Model with gamma 
distribution and log-link function. This model is appropriate since the distributions of hospital 
average costs are skewed to the right in all selected cohorts. In the second stage we regress patient 
health outcomes against the same patient characteristics included in the first stage model, plus 
hospital average costs and the regression residual obtained from the first stage model. We use a 
logistic regression with robust standard errors clustered within hospitals to allow for the correlation 
of patient health outcomes within hospitals. Statistical analysis was conducted using STATA 11 
statistical package. 
 
All models control for the following patients characteristics: 5 years age group (from 55-60 to 
95plus), sex, small area income deprivation index grouped in 4 quartiles, weighted Charlson 
comorbidity index (i.e., the sum of the weighted scores of the Charlson index), total number of 
secondary diagnosis, dummies for diabetes (ICD-10: E10-E14) chronic ischaemic heart disease (I20, 
I23-I25), chronic lower respiratory disease (J40-J47), heart failure (I50), renal failure (N17-N19), 
malignancy (any C code), and dummies for the year of admission (2006-2010). Also, we include 
controls for cohort specific patient conditions: hemorrhagic (I60, I62), ischemic (I63) or unspecified 
stroke (I64); ST elevation (I21.4) or non ST elevation in the AMI cohort; fixation (OPCS-4: W19, W20, 
W24, W25 covering primary open or closed reduction and internal or external fixation), prosthetic 
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replacement of head of femur (W46-W48), any other procedure (including non orthopaedic) and 
medical management (no procedure performed) in the hip fracture cohort.  
 
Finally, we control for hospitals serving urban or non-urban areas by including an indicator of the 
proportion of urban areas falling in the hospital catchment area (i.e. 20Km fix radius from the 
hospital postcode). The Office for National Statistics classifies small geographical areas units (LSOAs) 
into Urban, Town, and Villages according to their morphology28. Hospitals serving higher proportions 
of non-urban areas might face greater barriers to provide prompt and accessible services, which in 




Throughout this section hospital average costs are reported at 2010 prices and adjusted for regional 
price differentials as described earlier in the “Hospital costs” section.  Variation in hospital costs is 
large in each of the examined cohorts.  Figure 1 shows the distribution of hospital average costs 
calculated pooling together 2006-2010 data.  The hospital average cost for treating stroke patients is 
£2,785 and ranges from £1,389 to £4,724, for AMI patients is £3,034 ranging from £1,706 to £5,233, 
for hip fracture patients is £7,615 ranging from £1,065 to £5,278. Hospital costs include all the HRG 
services received by patients in selected cohorts from admission to final discharge as described in 
the “Hospital cost” section. 
  
Tables 1-4 report the characteristics of hospitals and selected cohorts by quartiles of hospital 
average costs and interquartile differences. Table 1 shows that the difference in average costs 
between upper and lower quartiles is £1,489 for stroke, £1,844 for AMI and £2,568 for hip fracture 
patients. Hospitals in the upper quartile of cost are in larger prevalence teaching hospitals in the 
stroke (10:1), AMI (12:0) and hip fracture cohort (9:3). Also, they are more likely to have fewer 
admissions per year in the hip fracture cohort (-88) and to some extent in the AMI cohort (-22), but 
have slightly higher admissions in the stroke cohort (+26). 
 
Table 2 shows the differences in the patient health risks for each cohort. Patients admitted in the 
lowest quartile of costs are in general very similar to patients admitted in the upper quartile in each 
of the examined cohorts. In the stroke cohort, small differences can be found in the weighted 
Charlson index (+0.048) and total secondary diagnoses (+0.222) suggesting that patients treated in 
high cost hospitals are to some extent sicker than patients admitted in low cost hospitals. In the AMI 
cohort, patients treated in the upper quartile of costs are younger (-1.2 years) and have a smaller 
weighted Charlson index (-0.062), but are more likely to have chronic ischaemic heart disease 
(+0.112) and slightly higher number of secondary diagnoses (+0.198). In the hip fracture cohort, 
patients treated in the top cost quartile have higher Charlson index (+0.061) and more secondary 
diagnoses (+0.253) again suggesting a slightly higher risk for such patients.  
 
Table 3 shows differences in process quality indicators by cost quartiles in 2010. In the stroke cohort, 
high cost hospitals are more likely to provide to their patients all 12 or all 9 key indicators of quality 
of care than least expensive hospitals (+4.7% and +7.7% respectively). Also, they are more likely to 
provide the 9 key indicators in 2008 (+10.4%). Among the most noticeable differences: patients 
admitted in high cost hospitals are more likely to spend 90% of their time in a stroke unit (+5.6%), to 
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be initially admitted in a stroke unit (+7.2%) and within 4 hours from call (+5.8%), and to receive a 
brain scan within 24 hours from stroke (+9.3%). In the AMI cohort, high cost hospitals are more likely 
be equipped for angioplasty services (+27.5%) and their non-ST elevation patients (nSTEMI) are more 
likely to be admitted to a cardiac unit (+7.6%) and to receive a coronary angiography (+19%). Both 
services are recommended by NICE to be provided to ST and non-ST elevation patients and in recent 
years have been progressively extended to the latter20. Among hospitals providing angioplasty 
services, high cost hospitals are less likely to perform this intervention within 150 min from call (-
3.2%) and to admit their patients directly to the intervention centre (-12.2%). In 2010, there are only 
68 hospitals providing primary angioplasty services in England and only 62 on routine basis20. Hip 
fracture patens admitted in high cost hospitals are more likely to have their cognitive functions 
assessed within 72 hours from surgery (+9.9%), attend an exercise programme within 12 weeks from 
fall (+24%) and have their home assessed for potential hazards (20.8%). However, only a limited 
number of hospitals reported a sufficient number of eligible cases (≥20) to calculate the last two 
indicators. Also, a number of quality indicators provide evidence of poorer care in high cost 
hospitals: their patients are less likely to be mobilise within 24h from surgery (-3.7%), receive 
appropriate analgesia within 60min of admission (-7.4%), blood pressure reading (-5%) and written 
information on fall prevention (-6.9%).     
 
Table 4 reports differences in health outcomes by cost quartiles. Stroke patients admitted in high 
cost hospitals are less likely to die in hospital after 30 days (-2%) or any time (-1.4%), but share a 
similar probability of being readmitted after 28 days (-0.2%) or 365 days (-0.8%) as compared with 
patients in low cost hospitals. AMI patients in high cost hospitals have similar probability of dying 
after 30 (-0.9%) days or any time (-0.9%), but lower probability of being readmitted after 28 days (-
1.6%) or 365 days (-3.4%). Hip fracture patients are more likely to die in hospital after 30 days (+1%) 
or any time (+1.9%) and to be readmitted after 28 days (+1.7%) and 356 days (+3.8%). 
 
Pairwise correlations between cost indicators and process quality indicators are in Table 5-6-7 for 
stroke, AMI and hip fracture cohorts respectively. Each process quality indicator is correlated with 
the three hospital cost indicators described in the statistical analysis: unadjusted, case-mix adjusted 
and case-mix adjusted in a subsample of 53 hospitals using PLICS.  We find evidence of a positive and 
statistically significant association between higher costs and better process quality for stroke 
patients consistent with descriptive statistics in Table 3. After adjusting for case-mix, higher costs are 
positively correlated with providing 9 key quality processes in 2010 (18.9% correlation with 0.03 p-
value) and in 2008 (27.1% with p-value < 0.01); access to brain scan within 24 hours from stroke 
shows the highest correlation with costs (31.3% with p-value < 0.001). The unadjusted cost indicator 
is positively correlated with a greater number of process quality indicators. Also, such a positive 
correlation is noticeably stronger in the sub-sample of hospitals using PLICS: providing 9 key quality 
processes in 2010 (44.9% correlation with p-value< 0.001) and in 2008 (44.8% with p-value < 0.001); 
among the single processes with the strongest correlation: brain scan within 24 hours (34.7% with p-
value < 0.05), spending at least 90% of stay on a stroke unit (39.4% correlation with p-value< 0.01), 
Initially admitted to a stroke unit (36.6% % p-value < 0.01), admitted in a stroke unit within 4 hours 
(29.1% with p-value < 0.05), aspirin or clopidogrel by 48 hours after stroke (40.9% p-value < 0.01).   
 
In the AMI cohort (Table 6), we find some evidence of a positive correlation between intensity of 
treatment and costs in nSTEMI patients receiving a coronary angiography (34.1% with p-value < 
 14 
 
0.001 in the case-mix adjusted indicator); some evidence of a positive correlation between hospital 
access to technology and costs in hospital providing primary angioplasty services (20% with p-value < 
0.05 in the case-mix adjusted indicator). Also, we find some evidence of negative correlation 
between costs and quality for indicators of prompt intervention: primary angiography within 150 
min from calling for help (-29.5% with p-value < 0.05) and direct admission to the interventional 
centre (-32% with p-value < 0.05). Similar results are obtained using the unadjusted cost indicator 
and are consistent with the descriptive statistics in Table 3. In the sample of hospitals using PLICS, 
we find similar correlations, although these are not statistically significant at 5% CI with the only 
exception of nSTEMI patients receiving a coronary angiography (35.6% with p-value < 0.05)  
 
In the hip fracture cohort (Table 7), we find little evidence of an association between process quality 
and costs. The only quality indicator significantly associated with costs is the assessment of cognitive 
function within 72h of surgery (23.5% with p-value < 0.05 in the case-mix adjusted indicator), no 
significant association is found with respect to other process quality indicators. Also, this result is not 
supported in the PLICS sample.        
 
Table 8 reports odds ratios of patient health outcomes against hospital average costs – measured in 
£1,000 units. Estimates are obtained using simple logistic regression and two-stage residual inclusion 
(2SRI) models as described in the “Statistical analysis” section. In the stroke cohort, we find evidence 
of a positive association between hospital average costs and better patient health outcomes. Odds 
ratios estimated from simple logistic regression are 0.947 (0.924-0.971, 95% CI) for in-hospital 
mortality after 30 days and 0.963 (0.939-0.988) for in-hospital mortality any time before patient 
discharge. In contrast, odds ratios for 28 days and 365 days emergency readmissions are not 
statistically different from zero: 0.989 (0.962-1.016) and 0.994 (0.972-1.016) respectively. Odds 
ratios estimated using 2SIR model show a slightly larger effect of costs consistent with results from 
the logistic regression: 0.862 (0.810-0.919, 95% CI) and 0.895 (0.829-0.966) for 30 days and any time 
in-hospital mortality and 1.040 (0.959-1.129) and 0.996 (0.934 to 1.061) for 30 days and 365 days 
readmissions.  
 
In the AMI cohort, we find no evidence of a significant association between costs and in-hospital 
mortality both after 30 days and any time before hospital discharge: the odds ratio for the former is 
0.995 (0.967-1.023) from logistic and 1.005 (0.887-1.138) from 2SRI model; odds ratio for the latter 
is 1.001 (0.973-1.031) from logistic and 1.022 (0.905-1.154) from 2SRI model. In contrast, odds ratios 
from simple logistic regression models show a small and negative association between costs and 28 
days and 365 days readmissions: 0.963 (0.942-0.984, 95% CI) and 0.964 (0.943-0.986) respectively. 
However, results for readmissions are not robust to the 2SRI model suggesting that they might be 
explained by unmeasured differences in patient health risk.  
 
Similarly, we find no evidence of an association between costs and mortality in the hip fracture 
cohort, both for 30 days and any time in-hospital mortality: the odd ratio for the former is 1.011 
(0.989-1.033) from logistic and 0.997 (0.930-1.068) from 2SRI model; odd ratio for the latter is 1.013 
(0.990 to 1.036) from logistic and 0.996 (0.924 to 1.073) from 2SRI model.  We find some evidence of 
a small and positive association between costs and readmissions occurring within 365 days, but no 
association with readmissions occurring within 28 days: the odd ratio for 28 days readmission is 
1.008 (0.993-1.025) from logistic regression and 1.028 (0.980-1.078) from 2SR model; the odd ratio 
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for 365 days readmission is 1.014 (1.001-1.027) from logistic regression and 1.033 (1.000-1.066) 
from 2SR model. Results of the estimated coefficients from the second stage of the 2SRI models are 
in Appendix 1-3 (Web Only files). Tests of the statistical significance of the instrumental variable 
used in the 2SRI models are in Appendix 4 (Web Only file).  
   
Sensitivity analysis and robustness checks 
 
We test the robustness of our results through a number of checks. First, we examined their 
sensitivity to the quality of the cost data reported by hospitals. We repeat our cost-process quality 
analysis in the subsample of 53 hospitals using a PLICS costing system, which allows for producing 
more accurate information on service costs. Also, we repeat our cost-health outcomes analysis in 
the same sample (Appendix 5 - Web Only file).  Results from the PLICS sample substantially support 
the predictions of the original analysis; for the stroke cohort the intensity and the statistical 
significance of the association between costs and quality are stronger than in the whole sample. 
 
Second, we test for the endogeneity of the hospital average costs with respect to patient health 
outcomes by examining the statistical significance of the residual estimated in the first stage of the 
2SRI model (Appendix 1 - Web Only file). We cannot reject the hypothesis of endogeneity for a few 
health outcomes, i.e. stroke 30 days and all in-hospital mortality (p-value<0.01 and p-value<0.05) 
and AMI 28 days readmissions (p-value<0.10). In these cases, predictions from a simple Logistic 
regression are biased and 2SRI models are consistent. In all other examined outcomes, there is no 
statistical evidence to support the hypothesis that the cost variable is endogenous, hence the logistic 
regression is preferred.  
 
Finally, we test the two assumptions underpinning our instrument, that there is a correlation 
between wages and hospital costs and that average area wages and patient health outcomes are 
independent (after controlling for all other variables in the model). The standard Chi-square tests for 
the statistical significance of the instrument support the first assumption in all examined cohorts 
(Appendix 4 - Web Only files). The assumption of independence cannot be tested directly. This 
assumption potentially could be invalidated by differences in average health and income between 
North and South of England. Therefore, we included controls for macro regions (North, Centre and 
South of England) in our 2SRI model and find no material differences in the results. Also, results from 
the Logistic regression are unchanged when controlling for Strategic Health Authorities or 
differences in the hospital Market Force Factors Index. We conclude that there is no reason to reject 
the claim that the chosen instrument is valid. 
 
     
Discussion 
 
Our study provides evidence that the relationship between costs and quality of hospital care 
depends on the treatment under scrutiny. We find that higher costs are associated with higher 
quality in stroke care. Patients admitted with a stroke in high cost hospitals are more likely to receive 
higher standards of care and less likely to die than patients admitted in low cost hospitals. We find 
some evidence that higher costs are associated with access to better technology and supply of more 
intensive treatment to AMI patients. However, we also find that lower costs are associated with 
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providing prompt intervention to these patients. Relative to health outcome, AMI patients admitted 
to high cost hospitals are no more likely to die or be readmitted than patients in low cost hospitals. 
Finally, we find little evidence that higher costs are associated with better process quality of care for 
patients admitted for a hip fracture and no evidence that higher costs are associated with lower 
mortality or readmissions for these patients.  
 
In the stroke cohort, we find clear evidence on the mechanism that might lead from higher costs to 
better health outcomes. High costs are associated with the supply of evidence based best standards 
of care, such as a brain scan within 24h of stroke, initial admission to a stroke unit, spending 90% of 
in hospital stay in the stroke unit, supply of aspirin or clopidogrel by 48 hours after stroke. Providing 
prompt and specialised intervention is central to improving health outcomes of stroke patients. An 
imaging of the brain within 4.5 hours from symptoms is required to identify the patients eligible for 
clot busting drug treatment (thrombolysis), which can dramatically improve patient health 
outcomes. Our study suggests that the provision of prompt and specialised services results in higher 
costs for the hospitals. However, higher costs in stroke care can be justified by better health 
outcomes. Our 2SRI model suggests that increasing hospital average costs by £1,000 pounds would 
reduce the probability of 30 days in-hospital mortality of 0,021 (0,012-0,031 - 95% confidence 
interval). This in turns would result in reducing 30 days in-hospital deaths by 5,266 (3,010-7,776) in 
return for a total incremental cost of about £250 million over 5 years period 2006-2010. 
Furthermore, unless applied with care, cost saving policies in stroke services run a high risk of 
compromising the quality of care and patients’ health.  
 
In the AMI cohort, evidence on the cost-outcome mechanism is mixed. We find higher costs in 
hospitals that are able to provide primary angioplasty services and hospitals providing primary 
angiography to nSTEMI patients. Both processes are recommended by NICE and MINAP since they 
are known to be associated with better health outcomes.  Also, we find some evidence that hospitals 
providing access to primary angioplasty within 150 minutes from call or giving direct access to the 
interventional centre have lower costs than other hospitals. Early intervention is known to 
dramatically improve health outcomes in AMI patients and might also be an indicator of hospital 
efficiency in the organisation of services. Therefore, early intervention might be indirectly associated 
with lower costs of care for AMI patients. Moreover, in recent years English hospitals have been 
organised into cardiac networks to coordinate the provision of hospital care, ambulance services, 
primary and tertiary care to the local population. The main objective of the network is to improve 
the way services are planned and delivered promoting the diffusion of homogenous standards in the 
quality of care20. This might have contributed to reducing inequalities in the standards of care 
delivered to AMI patients without having a noticeable impact on their costs. However, our analysis 
show that the net effect of higher costs on patient health outcomes is close to zero. Results from 
both process quality and health outcomes analyses might be interpreted as evidence that certain 
efficiency savings can be realised in the organisation of services to AMI patients without 
compromising on quality.    
 
In the Hip cohort, we find evidence of a substantial variation in hospital costs but no association 
between costs and process quality or costs and health outcomes. A series of national audits on the 
status of service of falls and bone health in older people has raised concerns about the standard of 
care delivered to hip fracture patients21. Several aspects of the organisation and provision of services 
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were audited against NICE guidelines for best practice and low rates of compliance were generally 
found across providers. We also find little evidence of differences in patient case-mix between high 
and low cost hospitals. Considering this evidence together, we conclude that there may be room for 
improving both efficiency and quality in the care delivered to hip fracture patients.  
 
The heterogeneity of our findings highlights the importance of using cohort specific indicators of 
hospital costs for this type of analysis. In England, secondary care services are supplied by a 
relatively small number of large multiservice providers often organised over multiple sites to cover a 
large local population. In 2010, there are 156 hospital trusts supplying acute services with about 
126,000 average admissions. Therefore, using a general indicator of hospital costs is unlikely to yield 
meaningful insights into the cost-quality relationship. Instead, our results strongly suggest the need 
for treatment-specific or condition-specific analysis. 
 
Monitor and the Department of Health are promoting the implementation of the PLICS system to 
improve reliability and accuracy of cost information reported by hospitals29. Our study also highlights 
the importance of implementing a more accurate costing system; this would allow for a better 
identification of the relationship between costs and quality as shown by our analysis in the sample of 
hospitals using PLICS. Although our general findings remain unchanged, the association between 
costs and quality is noticeably stronger and standard errors are smaller in the PLICS sample. Reliable 
data on service costs are the fundamental building block for any empirical investigation that aims at 
informing commissioners and planners of health services on value for money in health care. 
 
The study does have some limitations. The observational design limits the extent to which we can 
identify the components of care responsible for worse or better health outcomes, and the use of 
administrative data gives rise to the possibility of systematic coding and measurement errors. 
However, the study has some novel strength, which include the population-based longitudinal 
design, the examination of indicators of quality in the process of care and the use of an instrumental 
variable approach.  
 
Reducing hospital costs whilst maintaining or improving quality is at the centre of the health policy 
agenda in England and many other countries. The Department of Health is implementing an 
ambitious program of cost savings across all NHS hospitals. To that end, key strategies will be the 
creation of evidence-based guidelines, ‘smarter’ commissioning and improved hospital 
management. Our study produces the first evidence on the relationship between hospital costs and 
quality at the national level with which to inform these activities. By providing such evidence, we 
aim to help policy makers, commissioners and service providers focus their efforts more effectively 
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Table 1. Hospital characterisitcs by quartiles of average costs (2006-2010)
Stroke Lower quartile 2 3 Upper quartile Interquartile difference
(Upper-Lower)
cost indicator
hospitals average cost adjusted for regional price differentials (£1,000) 2.045 2.529 2.937 3.534 1.489
average admissions 327 348 409 353 26
teaching hospitals (by year) 1 4 8 11 10
total hospitals by cost quartiles (by year*) 38 35 37 41
AMI Lower quartile 2 3 Upper quartile
Total hospitals and costs
hospital average admission cost adjusted for regional price differentials (£1,000) 2.139 2.728 3.205 3.984 1.844
hospital average admissions 321              320           357           299              -22
teaching hospitals (by year) 0 4 7 12 12
total hospitals by cost quartiles (by year*) 36 38 36 39
Hip fracture
hospital average admission cost adjusted for regional price differentials (£1,000) 6.326 7.235 7.841 8.895 2.568
hospital average admissions 360              299           323           274              -86
teaching hospitals (by year) 3                 3              9              9                 6
total hospitals by cost quartiles (by year*) 37 35 39 38
Notes:
(*) Quartiles of hospital costs are calculated over the pooled sample of hospital units 2006-2010. Small differences in the number of hospitals in each quartile 






Table 2. Patients characterisitcs by quartiles of average costs (2006-2010)
Stroke Lower quartile 2 3 Upper quartile Interquartile difference
(Upper-Lower)
age 77.7 77.4 77.4 77.2 -0.4
female 0.529 0.527 0.528 0.526 -0.003
Weighted Charlson Index 1.724 1.743 1.773 1.772 0.048
secondary diagnoses in the first episode of care 4.732 4.764 5.054 4.953 0.221
diabetes (E10-E14) 0.165 0.165 0.159 0.161 -0.003
chronic ischaemic heart disease (I20, I23-I25) 0.172 0.178 0.175 0.171 -0.001
chronic lower respiratory disease (J40-J47) 0.091 0.096 0.093 0.089 -0.002
heart failure (I50) 0.048 0.047 0.048 0.042 -0.005
renal failure (N17-N19) 0.031 0.029 0.033 0.030 -0.001
malignancy (any C code) 0.039 0.041 0.044 0.041 0.002
income deprivation index 0.154 0.148 0.156 0.156 0.002
hemorrhagic stroke 0.069 0.076 0.083 0.091 0.022
ischemic stroke 0.584 0.573 0.575 0.616 0.031
unspecified 0.236 0.237 0.226 0.177 -0.059
total patients admitted 58,462         60,539       70,182       61,613         
AMI Lower quartile 2 3 Upper quartile
age 74.9 74.4 74.4 73.6 -1.2
female 0.397 0.399 0.394 0.381 -0.016
Weighted Charlson Index 1.939 1.927 1.921 1.877 -0.062
secondary diagnoses in the first episode of care 5.084 5.186 5.132 5.282 0.198
diabetes (E10-E14) 0.203 0.202 0.203 0.194 -0.009
chronic ischaemic heart disease (I20, I23-I25) 0.399 0.410 0.428 0.512 0.112
chronic lower respiratory disease (J40-J47) 0.133 0.136 0.131 0.122 -0.011
heart failure (I50) 0.185 0.169 0.171 0.173 -0.012
renal failure (N17-N19) 0.061 0.062 0.064 0.059 -0.002
malignancy (any C code) 0.037 0.034 0.036 0.030 -0.006
income deprivation index 0.142 0.155 0.161 0.163 0.021
non ST-elevation MI 0.110 0.103 0.109 0.103 -0.006
total patients admitted 54,406         54,305       60,893       49,801         
Hip fracture
age 83.6 83.5 83.0 83.2 -0.4
female 0.762 0.764 0.767 0.766 0.004
Weighted Charlson Index 0.831 0.861 0.898 0.892 0.061
secondary diagnoses in the first episode of care 5.747 5.778 5.977 5.999 0.253
diabetes (E10-E14) 0.112 0.112 0.118 0.117 0.005
chronic ischaemic heart disease (I20, I23-I25) 0.137 0.140 0.158 0.155 0.017
chronic lower respiratory disease (J40-J47) 0.118 0.124 0.132 0.136 0.018
heart failure (I50) 0.055 0.058 0.060 0.059 0.005
renal failure (N17-N19) 0.041 0.045 0.048 0.046 0.005
malignancy (any C code) 0.038 0.040 0.040 0.041 0.004
income deprivation index 0.129 0.129 0.165 0.170 0.041
fixation (W19, W20, W24, W25 covering primary open or closed reduction and inter 0.412 0.423 0.422 0.421 0.008
prosthetic replacement of head of femur (W46-W48) 0.376 0.397 0.377 0.354 -0.022
any other procedure (including non-orthopaedic ones if no fixation or replacemen 0.063 0.056 0.063 0.064 0.001
no procedure 0.149 0.124 0.137 0.162 0.013






Table 3. Process quality indicators by quartiles of average costs; % of compliance over elegible cases (2010)
Stroke Lower quartile 2 3 Upper quartile Interquartile difference
(Upper-Lower)
1. Spending at least 90% of stay on a stroke unit 59.6 58.7 63.2 65.2 5.6
2. Screening for swallowing disorders within 24hrs after admission 85.9 84.2 82.4 84.6 -1.3
3. Brain scan within 24hours of stroke 65.9 71.9 71.8 75.1 9.3
4. Aspirin or clopidogrel by 48 hours after stroke 90.1 92.2 92.6 94.1 4.1
5. Physiotherapy assessment within 72hrs of admission 91.3 92.2 90.0 92.1 0.8
6. Assessment by Occupational Therapist within 4 working days of admission 86.7 82.1 84.6 82.1 -4.6
7. Weighed at least once during admission 86.2 80.1 83.7 89.0 2.8
8. Mood assessed by discharge 82.5 80.8 77.1 82.1 -0.4
9. Rehabilitation goals agreed by multi-disciplinary team by discharge 94.4 96.9 92.4 92.4 -1.9
10. Swallow assessment within 72hours 86.5 86.6 83.3 85.3 -1.1
11. Initially admitted to a stroke unit 36.9 32.7 38.0 44.1 7.2
12. Rehab goals agreed by the multi-disciplinary team within 5 days of admission 79.0 80.6 74.9 78.1 -0.8
13. Diagnosis discussed with patient 77.3 82.6 78.8 78.3 1.1
14. Admitted to stroke unit within 4 hours 40.2 36.2 40.1 46.0 5.8
15. Initially admitted to a general assessment unit 58.1 62.0 55.0 50.5 -7.6
16. Receiving all key 12 indicators in 2010 (1-13 excl. 9) 18.1 15.4 12.3 22.8 4.7
17. Receiving all key 9 indicators in 2010 (1-9) 29.8 31.4 32.3 37.6 7.7
18. Receiving all key 9 indicators in 2008 (1-9) 12.7 11.1 17.5 23.1 10.4
hospitals submitting >=20 eligible cases 36 34 34 36
AMI Lower quartile 2 3 Upper quartile
1. Hospital providing primary angioplasty 34.2 52.7 61.6 61.7 27.5
hospitals submitting >=20 eligible cases 69 69 66 68
2. Primary angioplasty within 90 mins of arrival at interventional centre 88.8 84.9 86.5 89.1 0.3
hospitals submitting >=20 eligible cases 12 26 28 33
3. Primary angioplasy within 150 mins of calling for help 85.5 85.0 82.6 84.2 -1.3
hospitals submitting >=20 eligible cases 15 26 32 35
4. Primary angioplasy 150m of calling w direct adm to intervent centre 90.4 83.3 84.7 87.2 -3.2
hospitals submitting >=20 eligible cases 12 24 28 33
5. Patients with direct admission to Interventional Centre 91.8 86.8 81.0 79.6 -12.2
hospitals submitting >=20 eligible cases 19 30 38 37
6. nSTEMI patients admitted to cardiac unit or ward 49.8 53.7 57.1 57.4 7.6
hospitals submitting >=20 eligible cases 65 65 64 63
7. nSTEMI patients seen by a cardiologist or member of team 90.0 91.7 93.6 89.5 -0.5
hospitals submitting >=20 eligible cases 69 67 66 66
8. nSTEMI patients referred for or having coronary angiography 47.4 59.8 67.9 66.4 19.0
hospitals submitting >=20 eligible cases 67 67 66 65
Secondary prevention medications
9. Aspirin 98.3 98.4 98.5 98.5 0.2
hospitals submitting >=20 eligible cases 67 65 66 68
10. Beta blocker 94.1 94.9 95.8 96.2 2.1
hospitals submitting >=20 eligible cases 67 63 66 66
11. Satins 95.9 96.7 96.9 96.4 0.5
hospitals submitting >=20 eligible cases 67 65 66 68
12. ACE inhibitor 92.2 93.8 94.0 93.5 1.3
hospitals submitting >=20 eligible cases 69 65 66 66
13. Clopidogrel/Thienopyridine inhibitor 93.7 93.3 95.3 95.2 1.6
hospitals submitting >=20 eligible cases 69 63 66 68
Hip fracture
1. Adequate analgesia within 60 min of admission 69.6 69.7 64.4 62.2 -7.4
hospitals submitting >=20 eligible cases 24 25 27 26
2. Assessment of cognitive function within 72h of surgery 23.5 30.6 26.6 33.4 9.9
hospitals submitting >=20 eligible cases 22 17 24 20
3. Attempt to mobilise the patient within 24h of surgery 75.1 62.9 63.6 71.4 -3.7
hospitals submitting >=20 eligible cases 22 17 24 20
4. Documented lying and standing blood pressure readings 40.3 44.4 28.3 35.3 -5.0
hospitals submitting >=20 eligible cases 24 25 27 26
5. Patient attending exercise programme within 12w of fall 37.9 30.5 51.8 61.8 24.0
hospitals submitting >=20 eligible cases 9 8 16 9
6. Home hazard assessment of the patient’s own environment 30.0 4.4 18.0 50.8 20.8
hospitals submitting >=20 eligible cases 4 2 5 5
7. Anti-resorptive therapy for osteoporosis 60.9 60.2 56.8 64.2 3.2
hospitals submitting >=20 eligible cases 24 25 27 26
8. Written falls prevention info given to the patient or carer 18.4 16.9 13.7 11.5 -6.9
hospitals submitting >=20 eligible cases 24 25 27 26
9. Median time waited before operation (2006-2010) 1.1 1.0 1.1 1.0 -0.1






Table 4. Health outcomes by quartiles of hospital average costs (2006-2010)
Stroke Lower quartile 2 3 Upper quartile Interquartile difference
(Upper-Lower)
30 days in-hospital mortality 0.215 0.211 0.199 0.195 -0.020
patient dead at discharge 0.254 0.251 0.240 0.240 -0.014
28 days emergency readmission 0.114 0.122 0.116 0.116 0.002
365 days emergency readmission 0.395 0.404 0.397 0.404 0.008
total patients admitted 58,462         60,539       70,182       61,613         
AMI Lower quartile 2 3 Upper quartile
30 days in-hospital mortality 0.114 0.113 0.108 0.105 -0.009
patient dead at discharge 0.122 0.121 0.117 0.113 -0.009
28 days emergency readmission 0.176 0.171 0.166 0.160 -0.016
365 days emergency readmission 0.464 0.454 0.450 0.430 -0.034
total patients admitted 54,406         54,305       60,893       49,801         
Hip fracture
30 days in-hospital mortality 0.070 0.075 0.077 0.080 0.010
patient dead at discharge 0.101 0.109 0.109 0.120 0.019
28 days emergency readmission 0.117 0.121 0.130 0.134 0.017
365 days emergency readmission 0.369 0.373 0.396 0.407 0.038




Table 5. Pairwise correlations between hospital average costs and process quaity indicators - Stroke cohort (2010)
1. Spending at least 90% of stay on a stroke unit correlation 0.2036* 0.1553 0.3944*
p-value 0.0158 0.0668 0.0035
observarions 140 140 53
2. Screening for swallowing disorders within 24hrs after admission correlation 0.0874 0.0163 0.1459
p-value 0.3048 0.8488 0.2971
observarions 140 140 53
3. Brain scan within 24hours of stroke correlation 0.3609* 0.3126* 0.3467*
p-value 0 0.0002 0.011
observarions 140 140 53
4. Aspirin or clopidogrel by 48 hours after stroke correlation 0.2023* 0.1373 0.4088*
p-value 0.0165 0.1057 0.0024
observarions 140 140 53
5. Physiotherapy assessment within 72hrs of admission correlation 0.1047 -0.0342 0.1891
p-value 0.2181 0.6886 0.175
observarions 140 140 53
6. Assessment by Occupational Therapist within 4 working days of admission correlation 0.0168 -0.0782 0.1552
p-value 0.844 0.3586 0.267
observarions 140 140 53
7. Weighed at least once during admission correlation 0.1775* 0.0872 0.2103
p-value 0.0359 0.3057 0.1306
observarions 140 140 53
8. Mood assessed by discharge correlation -0.008 -0.0765 0.1712
p-value 0.9252 0.3689 0.2203
observarions 140 140 53
9. Rehabilitation goals agreed by multi-disciplinary team by discharge correlation -0.0644 -0.1102 0.1298
p-value 0.45 0.1948 0.3541
observarions 140 140 53
10. Swallow assessment within 72hours correlation 0.0296 -0.0378 0.2571
p-value 0.7287 0.6571 0.0631
observarions 140 140 53
11. Initially admitted to a stroke unit correlation 0.1731* 0.1387 0.3657*
p-value 0.0409 0.1021 0.0071
observarions 140 140 53
12. Rehab goals agreed by the multi-disciplinary team within 5 days of admission correlation 0.075 0.0039 0.1315
p-value 0.3783 0.9633 0.3481
observarions 140 140 53
13. Diagnosis discussed with patient correlation 0.1292 0.0256 0.2682
p-value 0.1282 0.7636 0.0521
observarions 140 140 53
14. Admitted to stroke unit within 4 hours correlation 0.1757* 0.1412 0.2911*
p-value 0.0379 0.0962 0.0345
observarions 140 140 53
15. Initially admitted to a general assessment unit correlation -0.1931* -0.1474 -0.3666*
p-value 0.0223 0.0822 0.0069
observarions 140 140 53
16. Receiving all key 12 indicators in 2010 (1-13 excl. 9) correlation 0.1823* 0.1221 0.4488*
p-value 0.0317 0.1521 0.0008
observarions 139 139 53
17. Receiving all key 9 indicators in 2010 (1-9) correlation 0.2804* 0.1887* 0.4484*
p-value 0.0008 0.0255 0.0008
observarions 140 140 53
18. Receiving all key 9 indicators in 2008 (1-9) correlation 0.2785* 0.2706* 0.4471*
p-value 0.0013 0.0018 0.0013
observarions 130 130 49
Note: 
Process quality indicators reported in 2010
Cost indicators calculated over 2009-2010
Only hospital submitting at least 20 elegible cases are included
Cost indicators










Table 6. Pairwise correlations between hospital average costs and process quaity indicators - AMI cohort (2010)
1. Hospital providing primary angioplasty correlation 0.1723* 0.2002* 0.2088
p-value 0.0418 0.0177 0.1374
observarions 140 140 52
2. Primary angioplasty within 90 mins of arrival at interventional centre correlation 0.0846 0.1013 0.1326
p-value 0.5593 0.4841 0.5466
observarions 50 50 23
3. Primary angioplasy within 150 mins of calling for help correlation -0.2755* -0.2947* -0.3229
p-value 0.0417 0.029 0.1154
observarions 55 55 25
4. Primary angioplasy 150m of calling w direct adm to intervent centre correlation -0.1041 -0.1254 -0.1531
p-value 0.4765 0.3905 0.4854
observarions 49 49 23
5. Patients with direct admission to Interventional Centre correlation -0.3747* -0.3210* -0.2161
p-value 0.0025 0.0103 0.2695
observarions 63 63 28
6. nSTEMI patients admitted to cardiac unit or ward correlation 0.1569 0.1053 0.0978
p-value 0.0723 0.2295 0.4994
observarions 132 132 50
7. nSTEMI patients seen by a cardiologist or member of team correlation -0.1168 -0.1004 -0.1819
p-value 0.1725 0.2412 0.2014
observarions 138 138 51
8. nSTEMI patients referred for or having coronary angiography correlation 0.3031* 0.3405* 0.3586*
p-value 0.0003 0 0.0106
observarions 136 136 50
Secondary prevention medications
9. Aspirin correlation -0.2263* -0.1578 0.0559
p-value 0.0078 0.0655 0.6971
observarions 137 137 51
10. Beta blocker correlation -0.1266 -0.0731 0.0089
p-value 0.1434 0.3996 0.9507
observarions 135 135 51
11. Satins correlation -0.0893 -0.1011 -0.1341
p-value 0.2993 0.2397 0.3481
observarions 137 137 51
12. ACE inhibitor correlation -0.0948 -0.1137 -0.0565
p-value 0.2705 0.1859 0.6908
observarions 137 137 52
13. Clopidogrel/Thienopyridine inhibitor correlation -0.0458 -0.0372 -0.1446
p-value 0.595 0.6663 0.3066
observarions 137 137 52
Note: 
Process quality indicators reported in 2010
Cost indicators calculated over 2009-2010
Only hospital submitting at least 20 elegible cases are included
Cost indicators










Table 7. Pairwise correlations between hospital average costs and process quaity indicators - hip fracture cohort (2010)
1. Adequate analgesia within 60 min of admission correlation -0.1244 -0.0498 -0.1065
p-value 0.2127 0.6191 0.5302
hospitals 102 102 37
2. Assessment of cognitive function within 72h of surgery correlation 0.2253* 0.2349* 0.1652
p-value 0.0406 0.0326 0.3583
hospitals 83 83 33
3. Attempt to mobilise the patient within 24h of surgery correlation 0.0486 0.0077 -0.1154
p-value 0.6624 0.9447 0.5226
hospitals 83 83 33
4. Documented lying and standing blood pressure readings correlation -0.0292 -0.0701 0.0921
p-value 0.771 0.4835 0.5877
hospitals 102 102 37
5. Patient attending exercise programme within 12w of fall correlation 0.2214 0.247 0.5209*
p-value 0.1587 0.1148 0.0465
hospitals 42 42 15
6. Home hazard assessment of the patient’s own environment correlation 0.4266 0.407 -0.3432
p-value 0.0994 0.1176 0.5054
hospitals 16 16 6
7. Anti-resorptive therapy for osteoporosis correlation 0.1055 0.0614 0.0518
p-value 0.2912 0.5401 0.761
hospitals 102 102 37
8. Written falls prevention info given to the patient or carer correlation -0.0291 -0.0641 0.0291
p-value 0.7712 0.5222 0.8641
hospitals 102 102 37
9. Median time waited before operation correlation -0.0769 -0.0474 -0.0296
p-value 0.3628 0.5757 0.8319
hospitals 142 142 54
Note: 
Process quality indicators reported in 2010
Cost indicators calculated over 2009-2010
Only hospital submitting at least 20 elegible cases are included









Table 8. Odds ratios (95% confidence interval) for death and readmission by patient cohorts (2006-2010). Adjusted for age, sex, deprivation fifth, and comorbidity
Cohort Exposure Logistic 2SIR Logistic 2SIR Logistic 2SIR Logistic 2SIR
Stroke Average costs (£1,000) 0.947 0.862 0.963 0.895 0.989 1.04 0.994 0.996
(0.924 to 0.971) (0.810 to 0.919) (0.939 to 0.988) (0.829 to 0.966) (0.962 to 1.016) (0.959 to 1.129) (0.972 to 1.016) (0.934 to 1.061)
Observations 250796 250796 250796 250796 189121 189121 189121 189121
# Hospital 151 151 151 151 151 151 151 151
AMI Average costs (£1,000) 0.995 1.005 1.001 1.022 0.963 1.040 0.964 0.956
(0.967 to 1.023) (0.887 to 1.138) (0.973 to 1.031) (0.905 to 1.154) (0.942 to 0.984) (0.956 to 1.132) (0.943 to 0.986) (0.877 to 1.043)
Observations 219405 219405 219405 219405 193483 193483 193483 193483
# Hospital 149 149 149 149 149 149 149 149
Hip Average costs (£1,000) 1.011 0.997 1.013 0.996 1.008 1.028 1.014 1.033
(0.989 to 1.033) (0.930 to 1.068) (0.990 to 1.036) (0.924 to 1.073) (0.993 to 1.025) (0.980 to 1.078) (1.001 to 1.027) (1.000 to 1.066)
Observations 217810 217810 217810 217810 194071 194071 194071 194071
# Hospital 149 149 149 149 149 149 149 149
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